A task force details its findings of the risks associated with using convalescent plasma using failure mode and effects analysis
Ranganayaki Nagaraj
Advertisement
Ranganayaki Nagaraj is manager of the Venture Center, Pune, India.
Articles by Ranganayaki Nagaraj
Advertisement
Latest Updated Articles
- A Systematic Evaluation of Risks and Mitigation Strategies for Convalescent Plasma Therapy for COVID-19
Published: February 3rd 2021 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Achieving Real Impact Navigating the Data and Regulatory Barriers to AI Adoption in Bio/pharma
2
How Is AI Transforming Biomanufacturing and Biopharma Workforce Training?
3
How Enzymatic Platforms May Change the Therapeutic RNA Supply Chain
4
BioPharma By the Numbers: Bioprocess Hiring Creating Capacity Constraints
5
